

Recent Advances in the Understanding and Management of Mucormycosis

Bhor Pratiksha J.¹, Thorat Sanket B.², Gadge Vinayak D.³, Belkar Gayatri B.⁴, Shinde Jyoti A.⁵, Shinde Pooja A.⁶, Tambe Sagar E.⁷

Samarth Institute of Pharmacy, Belhe, Maharashtra, India^{1,2,3,4,5,6}

Assistant Professor, Samarth Institute of Pharmacy, Belhe, Maharashtra, India⁷

vinayakgadge69@gmail.com

Abstract: *Mucormycosis is a fungal infection brimming a war in the shadow of covid-19 in India, Mucormycosis is caused by molds called as mucormycetes, corona virus disease caused by severe acute respiratory syndrome corona virus. (SARS-COV-2) has associated with wide range of bacterial and fungal infection. Aspergilliasis and Candida have been reported the main fungal pathogens for co-infection in the people of covid19. Covid-19 increases/ leads to weakened immune system preventing the body form effectively protecting against infection as a result individuals recovering from covid-19 are the risk for Mucormycosis. Steroid treatment for covid-19 may also act to suppress the body's immune response contributing to these increased Mucormycosis infection rate. Mucormycosis is highly tendency for contigious spread associated with poor progenosis and other immunosuppressive condition including corticosteroid theraphy and other drug theraphy are known risk factor for Mucormycosis.*

Keywords: *Mucormycosis, covid-19, corticosteroid theraphy, drug theraphy, immunosupression, fungal infection*

REFERENCES

- [1]. C. J. Kubin, T. H. McConville, D. Dietz et al. Characterization of Bacterial and Fungal Infections in Hospitalized Patients <https://doi.org/10.1093/ofid/ofab201>.
- [2]. G. sang, G. liang, W. liv, fungal co-infection associated with global covid-19 pandemic:
- [3]. 3) <https://www.medicalnewstoday.com/articles/covid-19-increases-black-fungus-infectionrisk-in-India>.
- [4]. Kazem Ahmadikia, Seyed Jamal Hashemi, Sadegh Khodavaisy, Muhammad Ibrahim Getso, Neda Alijani, Hamid Badali, Hossein Mirhendi, Mohammadreza Salehi, Azin Tabari, Mojtaba Mohammadi Ardehali, Mohammad Kord, Emmanuel Roilides, Sassan Rezaie. The double-edged sword of systemic corticosteroid therapy in viral pneumonia:
- [5]. M Richardson, The ecology of the Zygomycetes and its impact on environmental exposure. *ClinMicrobiol Infect.* 2009Oct; 15 Suppl5:2-9. Doi: 10.1111/j.1469-0691.2009.02972.x.
- [6]. Al-Ajam MR, Bizri AR, Mokhbat J, Widdon J and Lutwick L. Mucormycosis in the Eastern Mediterranean: a seasonal disease. *Epidemiol Infect.* 2006 Apr; 134(2): 341– 346.
- [7]. Fan Wu, Su Zhao, Bin Yu. A new coronavirus associated with human respiratory disease in China. *Nature* volume 579, pages265–269 (2020).
- [8]. WHO timeline covid-19, <https://www.who.int/News-room/detail/27-4-2020-who-timeline-covid-19>.
- [9]. Zumla A, Chan JF, Azhar EI et al, Coronaviruses - drug discovery and therapeutic options, *Nat Rev Drug Discov.* 2016 May;15(5):327-47. doi: 10.1038/nrd.2015.37. Epub 2016 Feb 12.
- [10]. Wang M, Cao R, Zhang L, Yang X et al, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Research* volume 30, pages269–271, <https://www.nature.com/articles/s41422-020-0282-0>.
- [11]. HayrunnisaNadaroglu, Antiviral drugs and plasma therapy used for Covid-19 treatment: a nationwide Turkish algorithm. DOI: 10.1080/03602532.2020.1803907.
- [12]. <https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1>.
- [13]. Singh AK, Singh R, Joshi SR, Mishra A, and Mucormycosis in COVID-19: A systematic review of cases

- reported worldwide and in India. *Diabetes MetabSyndr.* 2021 JulyAugust; 15(4): 102146.doi: 10.1016/j.dsx.2021.05.019.
- [14]. Shweta MallikarjunRevannavar, Supriya P S, LaxminarayanaSamaga and Vineeth V K.COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world. <https://casereports.bmj.com/content/14/4/e241663>.
- [15]. PayamTabarsi, NedaKhalili, MihanPourabdollah et al, COVID-19 associated rhinosinusitismucormycosis due to *Rhizopusoryzae*: A rare but potentially fatal infection occurring after treatment with corticosteroids. DOI: <https://doi.org/10.21203/rs.3.rs398594/v1>.
- [16]. Vijay Kumar Chennamchetty , SowmyaAdimulapu , Balaji Patel Kola, Post-COVID pulmonary mucormycosis- A case report. *IP Indian Journal of Immunology and Respiratory Medicine*. <https://www.ipinnovative.com/open-accessjournals>.
- [17]. https://rarediseases.org/race.diseases/mucor_mycosis.
- [18]. www.wikipedia.com.
- [19]. COVID-19 coronavirus epidemic has a natural origin, Scripps Research Institute <https://www.sciencedaily.com/releases/2020/03/200317175442.htm>
- [20]. K.L. Chow, D.P. McElmeel, H.G. Brown, M.S. Tabriz, E.C. Omi Invasive gastric mucormycosis: a case report of a deadly complication in an immunocompromised patient after penetrating trauma *Int. J. Surg. Case Rep.*, 40 (2017),
- [21]. Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19 *Cureus*, 2020; 12: e10726.
- [22]. Castrejón-Pérez, Ana Daniela et al. —Cutaneous mucormycosis. *Anais brasileiros de dermatologia*, 2017; 92,3: 304-311.
- [23]. Bonifaz A, Stchigel AM, Guarro J et al. Primary cutaneous mucormycosis produced by the new species *Apophysomyces mexicanus*, 2014; 52: 4428–4431.
- [24]. Artis, WM, Fountain, JA, Delcher, HK, Jones, HE. —A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. *Diabetes*, 1982 Dec.; 31: 1109-14.
- [25]. N.L. Smith, S. Phillips, S. Norwood Mucormycosis infection following trauma *Am. Surg.*, 2017; 83: 69-70.
- [26]. J.R. Köhler, A. Casadevall, J. Perfect The spectrum of fungi that infects humans *Cold Spring Harb. Perspect. Med.*, 5 (2014), Article a019273.
- [27]. Gebremariam T, Lin L, Liu M et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. *J Clin Invest*, 2016; 126: 2280–2294.
- [28]. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. *J Infect Dis.*, 2009; 200: 1002.
- [29]. Avery RK, Michaels MG. Strategies for safe living after solid organ transplantation external icon. *Am J Transplant*, 2013 May; 13 Suppl 4: 304-10.
- [30]. Tissot F, Agrawal S, Pagano L et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. *Haematologica*, 2017; 102: 433–444.